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EDITORIAL

EQUIVALENCE AND NON-INFERIORITY TRIALS IN A SNAPSHOT
Salima Kerai
Department of Paediatrics, Aga Khan University, Karachi-Pakistan

Randomized controlled trials conventionally entails superiority hypothesis where researcher is
interested to know whether a new treatment is better than the standard of care. However,
developing and testing novel techniques or therapies which are better than standard is not always
feasible. There are circumstances when effective treatment exists and new treatment is not
substantially better than existing treatment and conducting placebo controlled trials are unethical.
Then goal of the investigator changes; if new treatment is equivalent or non-inferior in comparison
to current standard of care with respect to a-priori set endpoints. The current paper aims to discuss
few key principles of equivalence and non-inferiority trial design and some challenges to think
about before designing or conducting these trials.
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Generally, when we think of a trial hypothesis of
interest, we think of superiority hypothesis whereby the
investigator intends to determine that a new
(experimental) treatment is better than the control
treatment (standard or placebo). In superiority trials
researcher claims that a new treatment is different (two
sided) or better (one sided) than the control arm and the
null hypothesis is that there is no difference between the
treatment arms. These trials are useful in testing new
therapies (preventive, therapeutic or rehabilitative) in
order to establish a standard of care or test therapies
which are better than the standards in place.
Sometimes developing novel techniques or
therapies which are better than the standard of care are
more difficult or treatment effect differs no more than a
specific amount. Then goal of the investigator changes;
if the new treatment is equally safe as thecurrent
standard of care. For this type of question, equivalence
design is the most suited where the researcher’s
hypothesis is that difference between two treatments is
equal to predefined ‘x’ which is called equivalence
margin. In other words, researcher tends to prove that
new treatment is no better or no worse than standard of
care as far as difference between two treatments is
within equivalence margin.
In a multicentre randomized controlled trial at
district level in Uganda, investigators claimed that the
safety and effectiveness of diagnosing and treatment of
incomplete abortion with misoprostol was equivalent
between midwives and physicians.2 They randomly
allocated women with first-trimester incomplete
abortion to clinical assessment and treatment with
misoprostol either by a physician or a midwife. The
Primary outcome was complete abortion not needing
surgical intervention within 14–28 days after initial
treatment with predefined equivalence of -4% to 4%.
The estimated risk difference for midwives versus
physicians group was -0.8% (95% CI -2.9 to 1.4) which
was falling within equivalence margin proving abortion

with misoprostol by midwives is equally safe and
effective when provided by physicians.
Besides, equivalence design requires a larger
sample size in order to rule out large differences and to
have a high probability of detecting a difference within a
margin. In equivalence designs researchers’ hypothesis
are revered as compared to superiority hypothesis. For
the equivalence design null hypothesis is that there is a
difference between two groups and researcher claims
that there is no difference or difference is within the
equivalence margin (two sided). Correspondingly, type I
and type II errors are also flipped. In equivalence design
type I error is failure to reject the null when difference
exists and type II error is wrongly rejecting null when
there is no difference.
However,
situations
arise
where
investigators are unable to accept claims of
equivalence. There are circumstances when effective
treatment exists and new treatment is not
substantially better than existing treatment and
conducting placebo controlled trials are unethical.
This issue can be addressed by non-inferiority
hypothesis where investigator claims that new
treatment is ‘no worse’ than existing treatment by
more than a pre-specified amount which is called
non-inferiority (NI) margin.
Similar to equivalence trials, we are detecting
small differences in non-inferiority trials with reversed
hypothesis and type I and type II errors. While
hypothesis of non-inferiority trials are one sided as
compared to equivalence hypothesis which are two
sided. Therefore, lesser sample size is required in noninferiority trials to reject the null. Because essentially in
non-inferiority trials, we are showing that new
treatment’s response if worse, still sufficiently close to
the established treatment response, so that new
treatment is as good as or not worse than the established
treatment.
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Non-inferiority trials offer other advantages in
experimenting therapies for endpoints like better safety
profile or lower cost or ease of administration or
compliance which are important from a clinical point of
view. For example, in case of childhood pneumonia,
amoxicillin is standard of care. Testing any new drug
against placebo would be unethical in presence
amoxicillin. In such case, the investigator can aim to test
non-inferiority of new drug in comparison to
amoxicillin using lower cost or safety as clinical
endpoints.
In an undergoing double blind randomized
controlled trial in Karachi, Pakistan, investigators
claimed that ‘no treatment’ (3 days of placebo) is noninferior to ‘treatment’ (3 days of amoxicillin-WHO
standard of treatment) in management of children with
WHO defined fast breathing pneumonia.1 Children 2–59
months of age with fast breathing, without any danger
sign are randomly allocated to receive either three days
of placebo or amoxicillin. Primary outcome is the
difference in cumulative treatment failure between the
two groups with a non-inferiority margin of 2.5%. For
analysis of non-inferiority trials, researchers need to get
a confidence interval (CI) for difference between two
arms and note that lower or upper bound of the CI does
not exceed NI margin (in predefined direction). There
are times when the new treatment is statistically better
than the control arm where CI is entirely above or below
zero showing superiority. In such cases, investigators
need to plan in advance that if non-inferiority is
established then they can test for superiority.
The important thing is to carefully choose
equivalence and non-inferiority margin, which is based
on clinical and statistical significance and prior research
experience. It should be carefully decided before
commencing the trial as it gives scientific credibility to
the trial. Equivalence and non-inferiority margin is the
minimum difference investigator can tolerate with
respect to specified endpoints in given direction. In
order to avoid type I error (false claim of equivalence or
non-inferiority when outcome is actually equivalent or
inferior), it is important to avoid margin that is too large
and has potential to adversely affect the participants. In
addition, the sample size must be sufficient enough on
the carefully selected margin, alpha and power to
declare equivalence and non-inferiority. Of note,
conservative margins require more sample size to detect
differences.
In contrast to intention to treat analysis,
equivalence and non-inferiority trials conventionally
incorporate per-protocol analysis. Intention to treat

analysis includes participants who were initially
randomized to treatment assignment whether they
adhere to the group or not or were lost to follow-up. It
has potential to bias results towards null if there is lots
of crossover among treatment groups. Per protocol
analysis on the other hand includes participants who
adheres to specific treatment group and excludes
protocol deviation and violations. However, excluding
these data points may also bias results in either
direction, particularly in survival trials where one might
discontinue study drug due to other fatal condition. It is
therefore advised to analyse equivalence and noninferiority trials by using both approaches. Moreover,
control arm must have a standard of care, otherwise, it
would be unethical if the comparator is less optimal
choice of treatment.
Quality of trial depends upon what endpoint is
chosen and how it is measured and how many lost to
follow-ups are there. In order to ensure validity of
outcome estimate, quality control measures need to be
in place to ensure adherence to standard operating
procedures, to minimize protocol deviations and
violations and minimize lost to follow-up. It should be
clearly stated how missing data would be handled if any
present and method used to deal with missing data.
Moreover, sensitivity analysis must be carried out to
ensure robustness of primary outcome with and without
missing data values. Specifically, in non-inferiority
trials, there should be consistency between type I error
rate and confidence interval margin. And hypothesis is
one sided based on one sided alpha which is
conventionally taken as 5% . Correspondingly, one
sided 95% CI or two sided 90% CI should be calculated.
The p-values are generally not required and if P value is
calculated, then it should be reported for one sided test
only.
Correct understanding of trial design is prerequisite for conducting and interpreting trials with valid
outcomes and to answer the research question in an
appropriate way.
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